Johnson & Johnson Exceeds Q4 Expectations with Strong Cancer Drug Sales

The pharmaceutical giant reports a 5.3% revenue increase, bolstered by Darzalex sales, while forecasting challenges in 2025 due to generics and currency impacts.

• Johnson & Johnson posted $22.52 billion in Q4 revenue, a 5.3% year-over-year increase, surpassing Wall Street estimates.
• Cancer drug sales, led by Darzalex with $3 billion in revenue, rose 19%, driving growth in the pharmaceutical division.
• The company recently announced a $14.6 billion acquisition of Intra-Cellular Therapies to expand its psychiatric drug portfolio.
• J&J forecasts 2025 revenue of $90.9-$91.7 billion, slightly below analysts' expectations, citing currency headwinds and generic competition for Stelara.
• Despite strong results, J&J shares fell over 1% as investors weighed ongoing talc litigation and slowing medical device sales in key markets like China.

0 Articles